Navigation Links
Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Aires Pharmaceuticals, Inc., announced today that it has successfully completed a $20 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P.  Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite™ to treat pulmonary arterial hypertension.  The agreement also includes a right to an exclusive worldwide license under pre-agreed conditions.  Including the initial acquisition payment plus potential additional regulatory and sales milestone payments, the deal with Novartis could reach $250 million.

The Series B financing includes new investor MPM Capital and the existing investor, ProQuest Investments.  Dr. William Greene, Managing Director of MPM Capital, will join Aires' Board of Directors.

"ProQuest Investments created Aires and has been a dedicated backer of the company since inception.  We are pleased that MPM and ProQuest will support the company, and along with Novartis share our enthusiasm for the potential of Aironite to help patients with pulmonary arterial hypertension," said Wendy Johnson, Founder, President and CEO of Aires.  The current financing will be sufficient to complete the planned clinical development program.

William Greene, M.D., Managing Director at MPM Capital, said, "We at MPM are excited about the potential of Aironite to impact the lives of pulmonary arterial hypertension patients and look forward to working with Aires in developing this novel approach to a devastating disease."

About Aironite™  

Aironite™ is an inhaled nitric oxide prodrug that has been shown in animal models to cause vasodilatation as well as potentially prevent or reverse the pulmonary artery smooth muscle cell proliferation associated with pulmonary arterial hypertension.  Significant preclinical development has been conducted by inventors Dr. Mark Gladwin and colleagues, formerly from the National Heart, Lung and Blood Institute of the NIH.  In early clinical trials conducted by Aires, Aironite administration resulted in nitric oxide production and reduction of pulmonary artery pressure.

About MPM Capital  

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.

About ProQuest Investments

Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management.  With a proven superior track record and over 40 investments the portfolio reflects the rich diversity of the healthcare industry and exemplifies commitment to fostering the growth of exceptional businesses.

About Aires Pharmaceuticals

Aires Pharmaceuticals, Inc., is a privately held drug development company developing Aironite for cardiopulmonary indications such as pulmonary hypertension.  The company is headquartered in San Diego, California.


'/>"/>
SOURCE Aires Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Buenos Aires Welcomes CPhI South America 2010
2. T-System Provides Free Medical Documentation Templates and Bi-Lingual Triage Questionnaires for Haiti Relief Medical Personnel
3. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
6. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
7. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
9. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
10. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
11. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
Breaking Medicine Technology:
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... Thailand (PRWEB) , ... August 19, 2017 , ... ... Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness ... in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business ...
Breaking Medicine News(10 mins):